Literature DB >> 27467651

Clinical evaluation of a securement device used on midline catheters.

Roy Ventura1, Chris O'Loughlin1, Boris Vavrik2.   

Abstract

Since the introduction of sutureless securement products for vascular access devices (VADs), there has been a great deal of discussion of their advantages and disadvantages in comparison with sutures. This includes questions related to VAD securement, patients' comfort, infection control, user-friendliness and potential complications of using the device. The literature review of the available evidence indicates the superiority of the novel sutureless devices in the aforementioned aspects. The authors collected data to further contribute in the analysis of the attributes of these products, namely Statlock™ and Grip-Lok™ (current devices). The authors then trialled, collected and analysed data from relevant healthcare practitioners on their perception of a novel sutureless 3M™ Tegaderm™ PICC/CVC Securement Device + Tegaderm™ I.V. Advanced Securement Dressing (trialled device) for midline VADs. Evaluation forms have been provided and filled in by the practitioners. The results showed that the trialled product is perceived as user-and patient-friendly, resulting in increased security of VAD and easier handling compared to the current devices. Overall, 70% of the evaluators stated that the trialled product has better or much better overall performance. The remaining 30% characterised the overall performance comparable with the current devices.

Entities:  

Keywords:  Catheter-related bloodstream infections; Catheters; Needlestick injuries; Securement; Vascular access

Mesh:

Year:  2016        PMID: 27467651     DOI: 10.12968/bjon.2016.25.14.S16

Source DB:  PubMed          Journal:  Br J Nurs        ISSN: 0966-0461


  1 in total

1.  Variation in use and outcomes related to midline catheters: results from a multicentre pilot study.

Authors:  Vineet Chopra; Scott Kaatz; Lakshmi Swaminathan; Tanya Boldenow; Ashley Snyder; Rachel Burris; Steve J Bernstein; Scott Flanders
Journal:  BMJ Qual Saf       Date:  2019-03-18       Impact factor: 7.035

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.